secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001558370-24-012137
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo Q2 net loss $10.1M; cash $27.9M; DA-1726 SAD fully enrolled
-------------------------------------------------------------------

- Net loss Q2 2024 $10.1M ($1.85/sh) vs $0.7M ($0.15/sh) Q2 2023; R&D expense rose to $8.1M from $2.4M.
- Cash $27.9M at June 30, 2024; expects to fund operations into Q2 2025; closed $20M upfront financing with up to $50M milestone warrants.
- DA-1726 SAD Part 1 fully enrolled (45 patients); top-line data expected Q3 2024; MAD Part 2 top-line Q1 2025.
- DA-1241 MASH Phase 2a top-line results expected Q4 2024; pre-clinical combination data with semaglutide presented.
- Signed joint research agreement for once-monthly DA-1726 formulation; out-licensed NB-01 for painful diabetic neuropathy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024012137/0001558370-24-012137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024012137/nrbo-20240814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer